10:29 AM EDT, 05/18/2026 (MT Newswires) -- Eli Lilly (LLY) was among the pharmaceutical firms highlighted in Monday's Supreme Court order list, which included widespread denials of certiorari in drugmaker-related and other commercial cases, according to the Court's May 18 orders.

The Court vacated and remanded several cases, including voting rights disputes, while rejecting review in multiple pharmaceutical and healthcare-related petitions, reducing the likelihood of near-term Supreme Court intervention in those matters.

The Court granted review in one education case while denying dozens of appeals across civil, criminal, regulatory, and healthcare matters, with Justice Sotomayor separately concurring in the denial of certiorari in a sentencing case in which relief had already been granted.

Shares of Eli Lilly were down 2.2% in Monday trading.

Price: 985.25, Change: -19.68, Percent Change: -1.96